by 
Polycystic Ovary Syndrome (PCOS) is one of the most common endocrine disorders in women of reproductive age. It is characterized by enlarged ovaries containing small cysts. PCOS diagnostic tests are done to identify the symptoms and treatment options that include obesity, menstrual irregularities, excess hair growth, depression, etc. Diagnostic tests involve ultrasound scanning of ovaries to check for cysts, hormonal blood tests to measure levels of testosterone, progesterone and insulin. Insulin resistance is a major cause of PCOS leading to weight gain and diabetes. The global PCOS diagnostic market plays a key role in early detection and management of PCOS through various testing tools.
The global PCOS diagnostic Market is estimated to be valued at US$ 1.2 billion in 2023 and is expected to exhibit a CAGR of 5.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Non-invasive diagnostic tests are gaining popularity among patients and healthcare providers for evaluating PCOS. Saliva and urine based tests are emerging as alternative to blood sampling for monitoring hormone levels. For instance, tests like Eve PCOS check hormone balance through urine and provide results within minutes at-home. Such simplified testing methods are improving accessibility and compliance for regular PCOS screening. Research on biomarkers is underway to develop sensitive and specific biomarkers for early and accurate PCOS diagnosis. This will boost use of liquid biopsy techniques using blood or other body fluids. Advancements in imaging technologies are also enabling improved ultrasound imaging for detection of ovarian cysts and other abnormalities.
Porter’s Analysis
Threat of new entrants: The threat of new entrants in the PCOS diagnostic market is low due to high costs of R&D, manufacturing, and brand establishment in the industry.
Bargaining power of buyers: The bargaining power of buyers in the PCOS diagnostic market is high due to the presence of many diagnostic players and differentiated products.
Bargaining power of suppliers: The bargaining power of suppliers in the PCOS diagnostic market is low due to the availability of substitutes and less differentiation in parts and components.
Threat of new substitutes: The threat of new substitutes in the PCOS diagnostic market is moderate due to technological advancement in alternative diagnosis procedures.
Competitive rivalry: The competitive rivalry in the PCOS diagnostic market is high due to many international players competing on the basis of product quality, innovation, and pricing.
Key Takeaways
The global PCOS diagnostic market is expected to witness high growth.
Regional analysis: North America is projected to dominate the global PCOS diagnostic market during the forecast period owing to the increasing PCOS patient pool and rising awareness regarding early diagnosis in the region.) Key players related content comprises Key players related content
Key players operating in the PCOS diagnostic market are Abbott Laboratories, AdaptaMedica S.A., and Bayer AG.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
